The US Food and Drug Administration (FDA) has accepted Vertex Pharmaceuticals’ completed new drug application (NDA) submission for suzetrigine, as the company’s non-opioid-based treatment for acute ...
On Monday, Goldman Sachs reaffirmed a Buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX), with a set price target of $598.00. At a recent event, Vertex presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback